Characterization of the cytokine profile of platelet rich plasma (PRP) and PRP-induced cell proliferation and migration: Upregulation of matrix metalloproteinase-1 and -9 in HaCaT cells

Korean Journal of Hematology

Volumn 46, Issue 4, 2011, Pages 265-273

  Park, Hong Bum ^a   Yang, Jeong Hee ^a   Chung, Kwang Hoe ^a  

^a CHA University   (South Korea)

Author keywords

Cell migration; Cell proliferation; Cytokine profile; Matrix metalloproteinase; Platelet rich plasma (PRP); Wound healing

Indexed keywords

EID: 84859832803     PISSN: 17387949     EISSN: 20929129     Source Type: Journal    
DOI: 10.5045/kjh.2011.46.4.265     Document Type: Article

References (40)

1. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005;111:3481-8.
2. Brass LF. Thrombin and platelet activation. Chest 2003;124(Suppl 3):18S-25S.
3. Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res 2006;99:1293-304.
4. Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. Circ J 2010;74:597-607.
5. Blair P, Flaumenhaft R. Platelet alpha-granules: basic biology and clinical correlates. Blood Rev 2009;23:177-89.
6. Badimon L, Vilahur G, Padró T. Lipoproteins, platelets and atherothrombosis. Rev Esp Cardiol 2009;62:1161-78.
7. Cattaneo M, Gachet C. ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol 1999;19:2281-5.
8. Jin J, Quinton TM, Zhang J, Rittenhouse SE, Kunapuli SP. Adenosine diphosphate (ADP)-induced thromboxane A(2) generation in human platelets requires coordinated signaling through integrin alpha(IIb)beta(3) and ADP receptors. Blood 2002;99:193-8.
9. Toriseva M, Kähäri VM. Proteinases in cutaneous wound healing. Cell Mol Life Sci 2009;66:203-24.
10. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
11. Libby P, Sukhova G, Lee RT, Galis ZS. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 1995;25(Suppl 2):S9-12.
12. Ganz P, Creager MA, Fang JC, et al. Pathogenic mechanisms of atherosclerosis: effect of lipid lowering on the biology of atherosclerosis. Am J Med 1996;101:4A10S-6S.
13. Lee E, Vaughan DE, Parikh SH, et al. Regulation of matrix metalloproteinases and plasminogen activator inhibitor-1 synthesis by plasminogen in cultured human vascular smooth muscle cells. Circ Res 1996;78:44-9.
14. Wang X, Qiu Y, Triffitt J, Carr A, Xia Z, Sabokbar A. Proliferation and differentiation of human tenocytes in response to platelet rich plasma: An in vitro and In vivo study. J Orthop Res 2011 [Epub ahead of print].
15. de Mos M, van der Windt AE, Jahr H, et al. Can platelet-rich plasma enhance tendon repair? A cell culture study. Am J Sports Med 2008;36:1171-8.
16. Caceres M, Martinez C, Martinez J, Smith PC. Effects of platelet-rich and -poor plasma on the reparative response of gingival fibroblasts. Clin Oral Implants Res 2011 [Epub ahead of print].
17. de Vos RJ, Weir A, van Schie HT, et al. Platelet-rich plasma injection for chronic Achilles tendinopathy: a randomized controlled trial. JAMA 2010;303:144-9.
18. Ranzato E, Patrone M, Pedrazzi M, Burlando B. Hmgb1 promotes wound healing of 3T3 mouse fibroblasts via RAGE-dependent ERK1/2 activation. Cell Biochem Biophys 2010;57:9-17.
19. Lova P, Campus F, Lombardi R, et al. Contribution of proteaseactivated receptors 1 and 4 and glycoprotein Ib-IX-V in the G(i)-independent activation of platelet Rap1B by thrombin. J Biol Chem 2004;279:25299-306.
20. Gear AR, Camerini D. Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirculation 2003;10:335-50.
21. Henn V, Steinbach S, Büchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001;98:1047-54.
22. Mellembakken JR, Solum NO, Ueland T, Videm V, Aukrust P. Increased concentrations of soluble CD40 ligand, RANTES and GRO-alpha in preeclampsia-possible role of platelet activation. Thromb Haemost 2001;86:1272-6.
23. Santoro MM, Gaudino G. Cellular and molecular facets of keratinocyte reepithelization during wound healing. Exp Cell Res 2005;304:274-86.
24. Lawson JH. The clinical use and immunologic impact of thrombin in surgery. Semin Thromb Hemost 2006;32(Suppl 1):98-110.
25. Schneider L, Cammer M, Lehman J, et al. Directional cell migration and chemotaxis in wound healing response to PDGF-AA are coordinated by the primary cilium in fibroblasts. Cell Physiol Biochem 2010;25:279-92.
26. Lederle W, Stark HJ, Skobe M, Fusenig NE, Mueller MM. Platelet-derived growth factor-BB controls epithelial tumor phenotype by differential growth factor regulation in stromal cells. Am J Pathol 2006;169:1767-83.
27. Rahimi RA, Leof EB. TGF-beta signaling: a tale of two responses. J Cell Biochem 2007;102:593-608.
28. Joo CK, Seomun Y. Matrix metalloproteinase (MMP) and TGF beta 1-stimulated cell migration in skin and cornea wound healing. Cell Adh Migr 2008;2:252-3.
29. Overall CM, López-Otín C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002;2:657-72.
30. Roussy Y, Bertrand Duchesne MP, Gagnon G. Activation of human platelet-rich plasmas: effect on growth factors release, cell division and in vivo bone formation. Clin Oral Implants Res 2007;18:639-48.
31. Su CY, Kuo YP, Nieh HL, Tseng YH, Burnouf T. Quantitative assessment of the kinetics of growth factors release from platelet gel. Transfusion 2008;48:2414-20.
32. Sanchez M, Anitua E, Orive G, Mujika I, Andia I. Platelet-rich therapies in the treatment of orthopaedic sport injuries. Sports Med 2009;39:345-54.
33. Harrison S, Vavken P, Kevy S, Jacobson M, Zurakowski D, Murray MM. Platelet activation by collagen provides sustained release of anabolic cytokines. Am J Sports Med 2011;39:729-34.
34. Mause SF, von Hundelshausen P, Zernecke A, Koenen RR, Weber C. Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler Thromb Vasc Biol 2005;25:1512-8.
35. VanWijk MJ, VanBavel E, Sturk A, Nieuwland R. Microparticles in cardiovascular diseases. Cardiovasc Res 2003;59:277-87.
36. Choi WS, Jeon OH, Kim DS. CD40 ligand shedding is regulated by interaction between matrix metalloproteinase-2 and platelet integrin alpha(IIb)beta(3). J Thromb Haemost 2010;8:1364-71.
37. Slupsky JR, Kalbas M, Willuweit A, Henn V, Kroczek RA, Müller-Berghaus G. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb Haemost 1998;80:1008-14.
38. Simsek S, Folman C, van der Schoot CE, von dem Borne AE. The Arg633His substitution responsible for the private platelet antigen Gro(a) unravelled by SSCP analysis and direct sequencing. Br J Haematol 1997;97:330-5.
39. Kalvegren H, Jönsson S, Jonasson L. Release of matrix metalloproteinases-1 and -2, but not -9, from activated platelets measured by enzyme-linked immunosorbent assay. Platelets 2011;22:572-8.
40. Cecchetti L, Tolley ND, Michetti N, Bury L, Weyrich AS, Gresele P. Megakaryocytes differentially sort mRNAs for matrix metalloproteinases and their inhibitors into platelets: a mechanism for regulating synthetic events. Blood 2011;118: 1903-11.